Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...
Models of biopharmaceutical production processes are more accurate and predictive if all downstream steps are considered together rather than individually. At least that’s according to researchers at ...
Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results